Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Herling, Marco  [Clear All Filters]
Journal Article
Lückemeier P, Radujkovic A, Holtick U, Kurch L, Monecke A, Platzbecker U, Herling M, Kayser S. Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study. Front Oncol. 2023;13:1208028.
Pralong A, Herling M, Holtick U, Scheid C, Hellmich M, Hallek M, Pauli B, Reimer A, Schepers C, Simon ST. Developing a supportive and palliative care intervention for patients with allogeneic stem cell transplantation: protocol of a multicentre mixed-methods study (allo-PaS). BMJ Open. 2023;13(8):e066948.
Bischof L, Ussmann J, Grimm J, Bill M, Brauer D, Backhaus D, Herrmann L, Merz M, Herling M, Metzeler KH, et al. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Leukemia. 2023.
Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, Merz M, Vucinic V, Franke G-N, Herling M, et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022;12(12):170.
Schwind S, Bischof L, Bill M, Grimm J, Ussmann J, Backhaus D, Brauer D, Thanh TPham, Merz M, Franke G-N, et al. Quantifying MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?. Hemasphere. 2024;8(3):e55.
Pemmaraju N, Deconinck E, Mehta P, Walker I, Herling M, Garnache-Ottou F, Gabarin N, Campbell CJV, Duell J, Moshe Y, et al. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk. 2023.
Hofmann SC, Koutcher K, Fabri M, Wahnschaffe L, Herling M, Zilberman E. Severely Itching Dermatitis and Palmoplantar Keratoderma as First Manifestation of T-cell Prolympho-cytic Leukaemia. Acta Derm Venereol. 2019.
Wahnschaffe L, Herling M. What to Look Out for when Transplanting T-Cell Prolymphocytic Leukemia. Acta Haematol. 2020:1-3.